DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
USA - NYSE:DBD - US2536512021 - Common Stock
65.18 USD
-0.07 (-0.11%)
65.18 USD
0 (0%)
Overall DBD gets a fundamental rating of 4 out of 10. We evaluated DBD against 35 industry peers in the Technology Hardware, Storage & Peripherals industry. Both the profitability and the financial health of DBD get a neutral evaluation. Nothing too spectacular is happening here. DBD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
DBD had positive earnings in the past year.
DBD had a positive operating cash flow in the past year.
In the past 5 years DBD reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
1.2 Ratios
With a decent Return On Assets value of 1.36%, DBD is doing good in the industry, outperforming 62.86% of the companies in the same industry.
With a decent Return On Equity value of 4.57%, DBD is doing good in the industry, outperforming 74.29% of the companies in the same industry.
DBD's Return On Invested Capital of 8.85% is fine compared to the rest of the industry. DBD outperforms 71.43% of its industry peers.
DBD had an Average Return On Invested Capital over the past 3 years of 5.12%. This is significantly below the industry average of 16.28%.
The 3 year average ROIC (5.12%) for DBD is below the current ROIC(8.85%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROIC | 8.85% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
The Profit Margin of DBD (1.37%) is better than 62.86% of its industry peers.
DBD's Operating Margin of 7.47% is fine compared to the rest of the industry. DBD outperforms 77.14% of its industry peers.
In the last couple of years the Operating Margin of DBD has grown nicely.
With a Gross Margin value of 25.48%, DBD perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
In the last couple of years the Gross Margin of DBD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DBD is destroying value.
The number of shares outstanding for DBD remains at a similar level compared to 1 year ago.
DBD has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, DBD has an improved debt to assets ratio.
2.2 Solvency
DBD has an Altman-Z score of 1.95. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
DBD's Altman-Z score of 1.95 is in line compared to the rest of the industry. DBD outperforms 60.00% of its industry peers.
DBD has a debt to FCF ratio of 3.71. This is a good value and a sign of high solvency as DBD would need 3.71 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 3.71, DBD is doing good in the industry, outperforming 68.57% of the companies in the same industry.
A Debt/Equity ratio of 0.84 indicates that DBD is somewhat dependend on debt financing.
The Debt to Equity ratio of DBD (0.84) is worse than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Altman-Z | 1.95 |
ROIC/WACC0.94
WACC9.38%
2.3 Liquidity
DBD has a Current Ratio of 1.36. This is a normal value and indicates that DBD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.36, DBD is in line with its industry, outperforming 51.43% of the companies in the same industry.
DBD has a Quick Ratio of 1.36. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.89, DBD perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
DBD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.07%.
DBD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 69.69% yearly.
Looking at the last year, DBD shows a decrease in Revenue. The Revenue has decreased by -2.86% in the last year.
Measured over the past years, DBD shows a decrease in Revenue. The Revenue has been decreasing by -3.18% on average per year.
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
3.2 Future
The Earnings Per Share is expected to grow by 11.87% on average over the next years. This is quite good.
Based on estimates for the next years, DBD will show a small growth in Revenue. The Revenue will grow by 2.83% on average per year.
EPS Next Y-3.97%
EPS Next 2Y13.81%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue Next Year2.09%
Revenue Next 2Y2.32%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
DBD is valuated rather expensively with a Price/Earnings ratio of 17.81.
Based on the Price/Earnings ratio, DBD is valued a bit cheaper than the industry average as 80.00% of the companies are valued more expensively.
DBD's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.34.
With a Price/Forward Earnings ratio of 13.04, DBD is valued correctly.
Based on the Price/Forward Earnings ratio, DBD is valued a bit cheaper than the industry average as 65.71% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of DBD to the average of the S&P500 Index (34.43), we can say DBD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.81 | ||
| Fwd PE | 13.04 |
4.2 Price Multiples
DBD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DBD is cheaper than 94.29% of the companies in the same industry.
DBD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. DBD is cheaper than 85.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.49 | ||
| EV/EBITDA | 7.41 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.81%
EPS Next 3Y11.87%
5. Dividend
5.1 Amount
DBD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
65.18
-0.07 (-0.11%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners105.22%
Inst Owner Change-1.04%
Ins Owners1.78%
Ins Owner Change0%
Market Cap2.39B
Revenue(TTM)3.69B
Net Income(TTM)50.60M
Analysts82.86
Price Target77.18 (18.41%)
Short Float %2.38%
Short Ratio4.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)0%
PT rev (3m)4.61%
EPS NQ rev (1m)-4.11%
EPS NQ rev (3m)-17.4%
EPS NY rev (1m)-0.41%
EPS NY rev (3m)4.56%
Revenue NQ rev (1m)-1.04%
Revenue NQ rev (3m)-5.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.81 | ||
| Fwd PE | 13.04 | ||
| P/S | 0.65 | ||
| P/FCF | 9.49 | ||
| P/OCF | 8.55 | ||
| P/B | 2.16 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.41 |
EPS(TTM)3.66
EY5.62%
EPS(NY)5
Fwd EY7.67%
FCF(TTM)6.87
FCFY10.54%
OCF(TTM)7.63
OCFY11.7%
SpS100.75
BVpS30.23
TBVpS-9.36
PEG (NY)N/A
PEG (5Y)N/A
Graham Number49.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROCE | 11.2% | ||
| ROIC | 8.85% | ||
| ROICexc | 9.91% | ||
| ROICexgc | 29.15% | ||
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% | ||
| FCFM | 6.82% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 20.59% | ||
| Cap/Sales | 0.75% | ||
| Interest Coverage | 2.89 | ||
| Cash Conversion | 68.06% | ||
| Profit Quality | 497.23% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | 1.95 |
F-Score7
WACC9.38%
ROIC/WACC0.94
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
EPS Next Y-3.97%
EPS Next 2Y13.81%
EPS Next 3Y11.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
Revenue Next Year2.09%
Revenue Next 2Y2.32%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.77%
EBIT Next 3Y13.69%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%
DIEBOLD NIXDORF INC / DBD FAQ
What is the fundamental rating for DBD stock?
ChartMill assigns a fundamental rating of 4 / 10 to DBD.
What is the valuation status for DBD stock?
ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.
What is the profitability of DBD stock?
DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.
How financially healthy is DIEBOLD NIXDORF INC?
The financial health rating of DIEBOLD NIXDORF INC (DBD) is 4 / 10.
Can you provide the dividend sustainability for DBD stock?
The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.